Denali Therapeutics (DNLI) Interest & Investment Income (2023 - 2026)

Denali Therapeutics (DNLI) has 4 years of Interest & Investment Income data on file, last reported at $8.9 million in Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $8.9 million, down 29.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.2 million (down 36.08% YoY), and the FY2025 annual result was $42.9 million, down 33.62% from the prior year.
• Interest & Investment Income steadied at $8.9 million in Q1 2026 per DNLI's latest filing, from $8.9 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $17.6 million in Q2 2024 and troughed at $8.9 million in Q1 2026.
• A 4-year average of $12.9 million and a median of $12.9 million in 2023 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2024 and 2025: Interest & Investment Income surged 44.22% in 2024, then sank 41.18% in 2025.
• A 4-year view of Interest & Investment Income shows it stood at $13.1 million in 2023, then grew by 15.48% to $15.2 million in 2024, then slumped by 41.18% to $8.9 million in 2025, then decreased by 0.09% to $8.9 million in 2026.
• Business Quant data shows DNLI's Interest & Investment Income at $8.9 million in Q1 2026, $8.9 million in Q4 2025, and $10.5 million in Q3 2025.